Risk of Second Non-Breast Primary Cancer in Male and Female Breast Cancer Patients: A Population-Based Cohort Study

Man-Hsin Hung1,4,5☯, Chia-Jen Liu2,6☯, Chung-Jen Teng4,6, Yu-Wen Hu1,4, Chiu-Mei Yeh3, San-Chi Chen2,4, Sheng-Hsuan Chien2,4, Yi-Ping Hung1,4, Cheng-Che Shen9,10, Tseng-Ji Chen3, Cheng-Hwai Tzeng2,4, Chun-Yu Liu1,4,7*

1 Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, 2 Division of Hematology and Oncology Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, 3 Department of Family Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, 4 School of Medicine, National Yang-Ming University, Taipei, Taiwan, 5 Program in Molecular Medicine, School of Life Sciences, National Yang-Ming University and Academia Sinica, Taipei, Taiwan, 6 Institute of Public Health, National Yang-Ming University, Taipei, Taiwan, 7 Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan, 8 Division of Oncology and Hematology, Department of Medicine, Far Eastern Memorial Hospital, Taipei, Taiwan, 9 Department of Psychiatry, Chiai Branch, Taichung Veterans General Hospital, Chiai, Taiwan, 10 Department of Information Management, National Chung-Cheng University, Chiai, Taiwan

☯ These authors contributed equally to this work.
*
cyliu3@vghtpe.gov.tw

Abstract

Female breast cancer patients have an increased risk of developing subsequent malignant diseases, but this issue is rarely discussed in regards to male breast cancer patients. Thus, we conducted a national survey that included 100,915 female and 578 male breast cancer patients to investigate the risk of second primary malignancy (SPM). During a follow-up period that included 529,782 person-years, 3,153 cases of SPM developed. Compared with the general population, the standardized incidence ratio (SIR) of SPM in breast cancer patients was 1.51 [95% confidence interval (CI): 1.46–1.56]. The observed risk was significantly higher in male patients (SIR 2.17, 95% CI 1.70–2.73) and in patients whose age at breast cancer diagnosis was 40 years or younger (SIR 3.39, 95% CI 2.80–4.07), compared to age-matched general population. Compared with the general population, the standardized incidence ratio (SIR) of SPM in breast cancer patients was 1.51 [95% confidence interval (CI): 1.46–1.56]. The observed risk was significantly higher in male patients (SIR 2.17, 95% CI 1.70–2.73) and in patients whose age at breast cancer diagnosis was 40 years or younger (SIR 3.39, 95% CI 2.80–4.07), comparing to age-matched general population. Compared with the overall female population, the SIRs of female breast cancer patients with uterine (SIR: 2.66, 95% CI: 2.37–2.98), thyroid (SIR: 2.30, 95% CI: 2.02–2.62), and bone and soft tissue (SIR: 2.16, 95% CI: 1.56–2.91) cancers were significantly increased. Male breast cancer patients also displayed significantly higher SIRs for thyroid (SIR: 13.2, 95% CI: 1.60–47.69), skin (SIR: 8.24, 95% CI: 3.02–17.94) and head and neck (SIR: 4.41, 95% CI: 2.35–7.54) cancers. Among breast cancer patients, risk factors significantly associated with SPM included male gender, older age, chemotherapy treatment and comorbidity with liver cirrhosis. From our analysis, we concluded that the risk of SPM was significantly higher for both male and female breast cancer patients compared with the general population, suggesting that more intensive surveillance may be needed, especially in high-risk patients.
Introduction

Breast cancer is one of the most common cancers worldwide and accounts for nearly a quarter of the newly diagnosed cancer cases reported for female patients each year.[1,2] Although rare, increased incidence in male breast cancer has been observed.[3–5] The overall survival of breast cancer patients, both male and female, has greatly improved in recent years.[6] The higher incidence of breast cancer and favorable disease outcome make issues for long-term survivors, especially the development of another malignant disease after breast cancer, become a more pertinent consideration.[7,8]

The risk of a second primary malignancy (SPM) in breast cancer patients has previously been discussed.[7–11] In general, the overall risk for developing a non-breast primary malignancy in female breast cancer patients has been reported to range from 18% to 30%, with higher incidences associated with early onset breast cancer diagnosis.[7–9] Using the Taiwan National Cancer Registry, Lee et al. demonstrated that female breast cancer patients, particularly those diagnosed with breast cancer at 50 years of age or younger, were associated with an increased SPM risk ratio.[8] However, these observations were restricted to female breast cancer patients, and there was no further discussion regarding the possible influence of treatments. Therefore, to better understand the risk of SPM in Asian male breast cancer patients, as well as the possible effects that treatment may have on both genders, a comprehensive investigation is needed.

Taiwan’s National Health Insurance (NHI) program provides comprehensive coverage to over 23 million people in Taiwan and is a valuable resource for investigating malignant diseases in breast cancer patients.[12] The nationwide population-based study conducted by the National Health Insurance Research Database (NHIRD) was analyzed in order to clarify the incidence rate, site of involvement, potential risk factors and subsequent outcome of second non-breast primary malignancies that affected breast cancer patients, including males.

Materials and Methods

Data Sources

This study was approved by the ethics committee of the Institutional Review Board of Taipei Veterans’ General Hospital. The study is based in part on data from the National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health and managed by National Health Research Institutes. The interpretation and conclusions contained herein do not represent those of Bureau of National Health Insurance, Department of Health or National Health Research Institutes.

Competing Interests: The authors have declared that no competing interests exist.

Study Population and Diagnosis of Breast Cancer

Patients with breast cancer were retrieved from the Registry of Catastrophic Illness according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 174–175. Cases registered between the dates of January 1, 1997, and December 31,
2011, were analyzed. In Taiwan, the application for a certificate of cancer-associated catastrophic illness requires pathological proof of malignancy with corresponding laboratory findings and imaging examinations provided for peer review. To avoid any bias, the following patient groups were excluded: patients diagnosed with breast cancer before January 1, 1997, patients diagnosed with malignancies prior to their breast cancer diagnosis \( (n = 2341) \), patients who completed less than one year of follow-up following a breast cancer diagnosis \( (that is, those patient whose breast cancer diagnosis were after December 31, 2010) \) \( (n = 95) \) and three patients who lacked complete personal information in the database. The exclusion of patients registered between 1995 to the date of January 1, 1997 is to avoid any patients whose breast cancers were diagnosed before the start of NHI but later registered in database as newly-diagnosed breast cancer. In addition, information was relatively more robust after Jan 1, 1997.

Information on comorbidities, including diabetes mellitus (DM), chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), dyslipidemia, liver cirrhosis and tuberculosis were also collected from the NHIRD.

**Statistical Analysis**

The main dependent variable analyzed was the occurrence of a second primary cancer. Subjects with another pathologically confirmed cancer diagnosis were identified from the Registry for Catastrophic Illness. Patients from the breast cancer cohort were followed until the development of cancer, death, dropout from the NHI program or until December 31, 2011.

The risk of a second primary cancer among the breast cancer cohort was determined using standardized incidence ratios (SIRs). This ratio includes the observed versus expected number of cancer occurrences. The expected number of cancers was calculated by multiplying the national incidence rate of various cancers according to gender, patient age (in 5-year intervals) and calendar year by the corresponding stratum-specific person-time accrued in the cohort. \[12\] The incidence rates for cancers among the general population were obtained from the Taiwan National Cancer Registry. For the SIRs, 95% confidence intervals (CIs) were estimated by assuming that the observed number of cancers followed a Poisson probability distribution. SIRs were also determined for patient subgroups according to gender and age. To avoid potential surveillance bias, subgroup analysis was stratified according to the time since a breast cancer diagnosis. SIRs were also estimated for each cancer type.

Demographic data, including patient age, gender, and comorbidities were compared for patients with and without second non-breast primary cancers using Fisher’s exact test for categorical variables and the Mann-Whitney U test for continuous variables. Univariate and multivariate Cox proportional hazard models were also utilized to identify predictors of second non-breast primary cancer development among patients previously diagnosed with breast cancer.

Datasets were extracted and computed using the Perl programming language (version 5.12.2). A Microsoft SQL Server 2008 (Microsoft Corp., Redmond, WA, USA) was used for data linkage, processing, and sampling. All statistical analyses were performed using SPSS statistical software version 19.0 for Windows (SPSS, Inc., Chicago, IL, USA). A p-value less than 0.05 was considered statistically significant.

**Results**

**Study population characteristics**

There were 101,493 breast cancer patients identified from the Catastrophic Illness Registry of the NHIRD. Of these patients, 100,915 \( (99.43\%) \) were female and 578 \( (0.57\%) \) were male. Overall, this cohort was observed for 529,782 person-years from January 1997 to December 2011, with a median follow-up period of 4.28 years \([interquartile range (IQR): 1.86–7.96]\). As shown
in Table 1, male patients tended to be older, have more comorbidities and received less chemotherapy and radiotherapy than female patients. Demographic data and treatment details for both gender groups are shown in Table 1.

### Second primary malignancy occurrence after breast cancer diagnosis

During the observation period, 3,153 breast cancer patients developed subsequent malignant disease. The SIR for a second non-breast primary cancer in these patients was 1.51 [95% CI: 1.46–1.56]. Further subset analysis demonstrated that the calculated SIR was higher for male patients (SIR: 2.17; 95% CI: 1.70–2.73) compared with female patients (SIR: 1.50; 95% CI: 1.44–1.55). Furthermore, a significant increase in SIR of second primary cancer was observed...

---

Table 1. Characteristics of patients with breast cancer.

|                         | Total       | Male       | Female     |
|-------------------------|-------------|------------|------------|
| Number of patients      | 101,493     | 578        | 100,915    |
| Person-years at risk    | 529,782     | 2,772.73   | 527,009    |
| Median follow-up, years (IQR) | 4.28(1.86–7.96) | 3.85(1.60–7.15) | 4.29(1.87–7.96) |
| Median age, years (IQR) | 50(44–59)   | 66(54–76)  | 50(44–59)  |
| Age at diagnosis, years |             |            |            |
| 20–29                   | 1484        | (1.5%)     | 3          | (0.5%)     |
| 30–39                   | 12133       | (12.0%)    | 28         | (4.8%)     |
| 40–49                   | 33995       | (33.5%)    | 67         | (11.6%)    |
| 50–59                   | 28572       | (28.2%)    | 119        | (20.6%)    |
| 60–69                   | 15491       | (15.3%)    | 129        | (22.3%)    |
| 70–79                   | 7387        | (7.3%)     | 150        | (26.0%)    |
| ≥80                     | 2431        | (2.4%)     | 82         | (14.2%)    |
| Comorbidities           |             |            |            |
| Diabetes mellitus       | 18,505      | (18.2%)    | 132        | (22.8%)    |
| COPD                    | 15,809      | (15.6%)    | 149        | (25.8%)    |
| Chronic kidney disease  | 8,264       | (8.1%)     | 69         | (11.9%)    |
| Liver cirrhosis         | 1,296       | (1.3%)     | 20         | (3.5%)     |
| Autoimmune diseases     | 8,227       | (8.1%)     | 31         | (5.4%)     |
| Dyslipidemia            | 23,801      | (23.5%)    | 134        | (23.2%)    |
| Breast Cancer Treatment |             |            |            |
| Hormone treatment       | 71,982      | (70.9%)    | 383        | (66.3%)    |
| Anastrozole             | 13,174      | (13.0%)    | 37         | (6.4%)     |
| Letrozole               | 13,883      | (13.7%)    | 38         | (6.6%)     |
| Exemestane              | 6,867       | (6.8%)     | 16         | (2.8%)     |
| Tamoxifen               | 66,950      | (66.0%)    | 367        | (63.5%)    |
| Chemotherapy            | 71,842      | (70.8%)    | 273        | (47.2%)    |
| Anthracycline           | 53,672      | (52.9%)    | 165        | (28.5%)    |
| Taxane                  | 25,837      | (25.5%)    | 83         | (14.4%)    |
| Cyclophosphamide        | 65,270      | (64.3%)    | 198        | (34.3%)    |
| Fluoropyrimidine        | 60,064      | (59.2%)    | 221        | (38.2%)    |
| Methotrexate            | 15,039      | (14.8%)    | 47         | (8.1%)     |
| Vinorelbine             | 9,215       | (9.1%)     | 30         | (5.2%)     |
| Platinum                | 8,059       | (7.9%)     | 40         | (6.9%)     |
| Trastuzumab             | 7,064       | (7.0%)     | 13         | (2.2%)     |
| Radiotherapy            | 46,581      | (45.9%)    | 162        | (28%)      |

doi:10.1371/journal.pone.0148597.t001
in all patients whose breast cancer was diagnosed at an age younger than 40 years (SIR: 3.39, 95% CI 2.80–4.07), but this risk decreased as the patient age at the time of breast cancer diagnosis increased (Table 2 and Fig 1). It is important to note that the SIRs for male patients in all of the different age subgroups were higher than those observed for female patients (Fig 1). A summary of the sub-analyses performed is provided in Table 2.

The SIRs for Specific Cancers

As shown in Fig 2, the SIRs for specific types of second primary malignancies in breast cancer patients were found to vary according to gender. For example, in female patients, the most commonly observed cancer types were colon and rectal (n = 543), followed by lung and mediastinum (n = 415) and uterus (n = 298) (Table 3) cancers. Relative to the general population, female patients with a prior breast cancer diagnosis were found to have a significantly higher risk of developing a subsequent cancer of the uterus (SIR: 2.66; 95% CI: 2.37–2.98), thyroid (SIR: 2.30; 95% CI: 2.02–2.62), ovary (SIR: 2.05; 95% CI: 1.75–2.38), kidney (SIR: 1.87; 95% CI: 1.57–2.20), stomach (SIR: 1.36; 95% CI: 1.15–1.60), liver (SIR: 1.18; 95% CI: 1.05–1.31), pancreas (SIR: 1.32; 95% CI: 1.01–1.70), lung and mediastinum (SIR: 1.52; 95% CI: 1.38–1.67), bone and soft tissue (SIR: 2.16; 95% CI: 1.56–2.91), as well as hematologic malignancies (SIR: 1.70; 95% CI: 1.47–1.96). For male patients, head and neck cancer was the most common second primary malignancy after breast cancer (n = 13), followed by colon and rectum (n = 12) and lung and mediastinum (n = 11) cancers. However, compared with the general population, the risk of thyroid cancer (SIR: 13.2; 95% CI: 1.60–47.69), skin cancer (SIR: 8.24; 95% CI: 3.02–17.94), colon cancer (SIR: 2.18; 95% CI: 1.31–3.80), and head and neck cancer (SIR: 4.41; 95% CI: 2.35–7.54) were markedly higher in male patients. To investigate the influence of a potential surveillance bias, SIR analyses were also performed, which excluded patients with second primary cancers diagnosed within one year after the initial breast cancer diagnosis. This model yielded similar results (Table 3 and Table A in S1 File).

Predictors of second non-breast primary malignancies in breast cancer patients

Using the SIR method, we highlighted the increasing risk of developing a non-breast malignancy in breast cancer patients, as compared with the age- and gender-matched general population (Table 2 and Fig 1). We also used Cox proportional hazards analysis to investigate factors predicting higher SPM risk within breast cancer patients (Table 4). Notably, older age [increased age by every ten years, hazard ratio (HR): 1.45 (1.40–1.49); p < 0.0010], male gender [HR: 3.01; 95% CI: 2.38–3.80; p < 0.001], use of chemotherapy (HR: 1.26; 95% CI: 1.16–1.36; p < 0.001), and the presence of liver cirrhosis (HR: 2.84; 95% CI: 2.32–3.47; p < 0.001) were found to be significantly associated with the incidence of a second non-breast malignancy in breast cancer patients (Table 4).

Discussion

Development of a second primary malignancy is one of the most significant concerns for breast cancer survivors, especially in the current era where breast cancer survival has been significantly improved by new treatments and early detection.[9] Accordingly, a growing need exists for evaluating the risk of second primary malignancy in both male and female breast cancer patients. In the present study, 101,493 breast cancer patients, including 578 male patients and 100,915 female patients, were analyzed for a total of 529,782 patient-years. To the best of our knowledge, this is the largest population-based study to investigate the risk for developing a subsequent non-breast malignant disease in Asian breast cancer patients. Furthermore, the
extensive coverage of the NHI, their strict diagnostic criteria, and the data available from the large and detailed database maintained by the NHIRD, facilitated an unbiased study of second non-breast malignancy incidence in breast cancer patients and eliminated potential confounding factors.

Several reports have suggested that differences in hormonal and genetic predispositions between male and female patients can affect breast cancer diagnoses and clinical outcomes. In the present study, we showed that breast cancer survivors of both genders exhibited a significantly higher risk for developing another primary malignancy compared with the general population and that male breast cancer patients had a higher excess risk compared with female breast cancer patients. (Fig 1 and Table 2) While the risk of second primary malignancy in female breast cancer patients has been addressed in different cohorts, fewer studies have examined a potential increased risk in male breast cancer patients. Aside from our study, Curtis and his colleagues analyzed data from the Surveillance, Epidemiology, and End Result Program (SEER) database, which enrolled patients that were diagnosed during the year from 1970 to 2000, and showed a marginal increased risk of subsequent cancer in male breast cancer patients (ratio of observed to expected cancer = 1.11), whereas the increased risk in female patients was significant (O/E = 1.18). Differences in the risk patterns presented by Curtis et al. compared with those in the current study may reflect the underlying racial or ethnic disparities, differences of life-style and environmental risks or changes in treatment. It is important to note that a higher percentage of male breast cancer patients had comorbid diseases, such as DM, COPD, CKD and liver cirrhosis, compared with female patients, whereas female patients were more likely to have autoimmune diseases at the time of breast cancer diagnosis. (Table 1) The underlying comorbidities may also impact the overall risk of developing second primary cancer.

In the present study, we show that the age at breast cancer diagnosis was a major determinant of the relative risk for subsequent malignancy in breast cancer patients of both genders. The indicated SIRs for patients diagnosed with breast cancer at an age of 30 years or younger, was more than five times higher than that of patients who were diagnosed at an age greater

### Table 2. Standardized incidence ratios according to gender, age at diagnosis and duration of breast cancer.

| Characteristics | Total | Male | Female |
|-----------------|-------|------|--------|
|                 | Observed | Expected | SIR (95% CI) | Observed | Expected | SIR (95% CI) | Observed | Expected | SIR (95% CI) |
| All cancers     | 3,153 | 2,090.51 | 1.51(1.46–1.56) | 73 | 33.63 | 2.17(1.70–2.73) | 3,080 | 2,056.89 | 1.50(1.44–1.55) |
| Age at diagnosis, years |
| 20–29 | 8 | 1.15 | 6.96(3.01–13.72) | 0 | 0.00 | 0.00(0.00–1518.06) | 8 | 1.15 | 6.98(3.01–13.75) |
| 30–39 | 106 | 32.47 | 3.26(2.67–3.95) | 3 | 0.10 | 29.70(6.12–86.80) | 103 | 32.37 | 3.18(2.60–3.86) |
| 40–49 | 510 | 266.60 | 1.91(1.75–2.09) | 2 | 0.78 | 2.58(0.31–9.31) | 508 | 265.82 | 1.91(1.75–2.08) |
| 50–59 | 928 | 582.02 | 1.59(1.49–1.70) | 11 | 2.95 | 3.73(1.86–6.68) | 917 | 579.07 | 1.58(1.48–1.69) |
| 60–69 | 774 | 556.36 | 1.39(1.29–1.49) | 14 | 6.19 | 2.26(1.24–3.79) | 760 | 550.17 | 1.38(1.28–1.48) |
| 70–79 | 582 | 451.33 | 1.29(1.19–1.40) | 18 | 13.55 | 1.33(0.79–2.10) | 564 | 437.78 | 1.29(1.18–1.40) |
| > 80 | 245 | 200.59 | 1.22(1.07–1.38) | 25 | 10.07 | 2.48(1.61–3.67) | 220 | 190.53 | 1.15(1.01–1.32) |
| Duration of breast cancer |
| 0–1 | 479 | 328.54 | 1.46(1.33–1.59) | 15 | 5.64 | 2.66(1.49–4.38) | 464 | 322.90 | 1.44(1.31–1.57) |
| 1–5 | 1,456 | 957.61 | 1.52(1.44–1.60) | 37 | 16.00 | 2.31(1.63–3.19) | 1,419 | 941.61 | 1.51(1.43–1.59) |
| > 5 | 1,218 | 804.37 | 1.51(1.43–1.60) | 21 | 11.99 | 1.75(1.08–2.68) | 1197 | 792.38 | 1.51(1.43–1.60) |

SIR Standardized incidence ratio; CI confidence interval; N/A not applicable.

doi:10.1371/journal.pone.0148597.t002
than 80 years. These findings are consistent with previously published data.\cite{7,9,11} Some researchers have argued that the increased risk for a second cancer in younger patients may be related to the administration of intensive treatments and/or a longer follow-up period.\cite{17–20}

However, in the present study and in studies using Scandinavian cohort data\cite{7}, age-related risk differences remained significant even after the adjustment for possible confounding factors, such as calendar year of breast cancer diagnosis, duration of follow-up, and breast cancer treatment. These findings suggest that certain genetic predispositions are associated with early onset breast cancer and may contribute to the higher risk of developing a second primary cancer\cite{21}. The higher SIR we observed in young breast cancer patients may reflect this distinct biology presented in young breast cancer patients and a relative lower cancer incidence in the age-matched general cohort.

When specific types of cancer were assessed, male and female patients of the current cohort were found to have distinct patterns of involvement (Table 3 and Fig 2). These findings highlight several points. First, genetic alternations may contribute to the development of second malignancy in breast cancer patients. According to literatures, the mutations of BRCA genes were associated with increased risk of breast, ovary and colon cancer, whereas the elevated risk of uterine cancer, thyroid cancer and kidney cancer correlated with loss-of-function mutations
in PTEN[21–23]. Though information regarding these genetic alterations were lacking, we observed increasing risk of above-mentioned cancers after breast cancer diagnosis in our patients, particularly an increase in SIRs for colon and thyroid cancers in male breast cancer patients and ovarian and kidney cancers in female patients. Second, treatments for breast cancer may affect the risk of developing a second malignancy. In line with previous reports[9,11], we found an increased risk of developing thyroid, lung, stomach, pancreas, skin, uterus, head and neck cancers, as well as hematologic malignancies in our cohorts. The developments of the cancers listed above were considered to be associated with radiotherapy, chemotherapy, and tamoxifen (for uterus cancer)[9,11]. In our study, we also analyzed the impacts of different treatment modalities in a multivariate analysis. For all cancer in general, only chemotherapy remained a significant factor after adjusting for other risk factors, including age, sex and comorbidities (Table 4). When we focused on uterus cancer, the impact of tamoxifen was shown (Table B in S1 File). Additionally, the relatively small number of cases in certain cancer types, especially in male breast cancer patients, may also limit the statistical power. Third, smoking and other life-style factors may influence the risk of second primary cancer [24,25]. Limited by our database, the exact smoking condition was unknown in our patients, but we found high prevalence of COPD in our cohort, especially in male patients (Table 1). Interestingly, if we assumed COPD as a surrogate for smoking exposure, we found that COPD was significantly associated with increasing risks of subsequent lung cancer (Table C in S1 File).

Furthermore, in line with previous studies [9], a significant decrease in the risk of subsequent cervical cancer in female breast cancer patients was observed in the present study. The exact cause for the decreasing risk was not fully understood, but Curtis et al. had postulated that lower rate of smoking and lifestyle differences among breast cancer survivors in the SEER
database may be responsible for this "protective" effect [9]. As mentioned above, we’re not able to investigate the impact of these personal habits to the risk of cervical cancer in our cohort, and further studies are needed. Lastly, frequent medical consultation and image examinations, such as computerized tomography scan of chest performed for staging or follow-up of breast cancer, may increase the detection of cancers, like thyroid, lung and colon cancer, and contribute to the higher SIRs we observed in present study.

In the present study, we also sought for possible risk factors of developing a non-breast primary malignancy in breast cancer patients. Similar to past reports[11], older patients and patients who had received chemotherapy were associated with a significantly higher risk of developing a second non-breast primary cancer (Table 4). The higher risk of developing a subsequent malignancy we shown in older breast cancer patients may be explained by the notion that aging is an important risk factor for most of the cancer types. In addition, we found that male gender and the presence of liver cirrhosis also significantly impacted this second cancer risk. Liver cirrhosis is a clear contributor to liver cancer and also to malignancies of the esophagus, pancreas and lung[26]. In this study, we found that cirrhosis significantly contribute to the

Table 3. Standardized incidence ratios for specific cancer types among patients with breast cancer (follow-up more than 1 year).

| Site of cancers                     | Total              | Male                  | Female               |
|------------------------------------|--------------------|-----------------------|----------------------|
|                                    | Observed | Expected | SIR (95% CI) | Observed | Expected | SIR (95% CI) | Observed | Expected | SIR (95% CI) |
| All cancers                         | 2,674    | 1,761.98 | 1.52 (1.46–1.58) | 58       | 27.99    | 2.07 (1.57–2.68) | 2,616    | 1,733.99 | 1.51 (1.45–1.57) |
| Head and neck                       | 91       | 71.47    | 1.27 (1.03–1.56) | 10       | 2.41     | 4.15 (1.99–7.63) | 81       | 69.06    | 1.17 (0.93–1.46)  |
| Digestive                          | 978      | 732.09   | 1.34 (1.25–1.42) | 21       | 12.37    | 1.70 (1.05–2.60) | 957      | 719.73   | 1.33 (1.25–1.42)  |
| Esophagus                           | 10       | 9.53     | 1.05 (0.50–1.93) | 0        | 0.76     | 0.00 (0.00–4.85) | 10       | 8.77     | 1.14 (0.55–2.10)  |
| Stomach                             | 134      | 92.63    | 1.45 (1.21–1.71) | 4        | 1.98     | 2.02 (0.55–5.18) | 130      | 90.65    | 1.43 (1.20–1.70)  |
| Colon and rectum, Anus              | 484      | 342.67   | 1.41 (1.29–1.54) | 10       | 4.60     | 2.18 (1.04–4.00) | 474      | 338.07   | 1.40 (1.28–1.53)  |
| Liver and biliary tract             | 291      | 246.66   | 1.18 (1.05–1.32) | 6        | 4.46     | 1.34 (0.49–2.93) | 285      | 242.20   | 1.18 (1.04–1.32)  |
| Pancreas                            | 59       | 40.60    | 1.45 (1.11–1.87) | 1        | 0.56     | 1.77 (0.04–9.87) | 58       | 40.04    | 1.45 (1.10–1.87)  |
| Lung and mediastinum                | 352      | 238.05   | 1.48 (1.33–1.64) | 10       | 4.88     | 2.05 (0.98–3.77) | 342      | 233.17   | 1.47 (1.32–1.63)  |
| Bone and Soft tissue                | 38       | 16.86    | 2.25 (1.60–3.09) | 0        | 0.21     | 0.00 (0.00–17.78) | 38       | 16.65    | 2.28 (1.62–3.13)  |
| Skin                                | 44       | 44.55    | 0.99 (0.72–1.33) | 3        | 0.61     | 4.88 (1.01–14.26) | 41       | 43.94    | 0.93 (0.67–1.27)  |
| Genitourinary                       | 719      | 433.70   | 1.66 (1.54–1.78) | 9        | 5.72     | 1.57 (0.72–2.99) | 710      | 427.99   | 1.66 (1.54–1.79)  |
| Cervix                              | 131      | 150.04   | 0.87 (0.73–1.04) | N/A      | N/A      | N/A            | 131      | 150.04   | 0.87 (0.73–1.04)  |
| Uterus                              | 265      | 94.71    | 2.80 (2.47–3.16) | N/A      | N/A      | N/A            | 265      | 94.71    | 2.80 (2.47–3.16)  |
| Ovary                               | 142      | 69.81    | 2.03 (1.71–2.40) | N/A      | N/A      | N/A            | 142      | 69.81    | 2.03 (1.71–2.40)  |
| Prostate                            | 7        | 3.61     | 1.94 (0.78–4.00) | 7        | 3.61     | 1.94 (0.78–4.00) | N/A      | N/A      | N/A            |
| Bladder                             | 60       | 50.83    | 1.18 (0.90–1.52) | 2        | 1.42     | 1.41 (0.17–5.09) | 58       | 49.41    | 1.17 (0.89–1.52)  |
| Kidney                              | 114      | 64.70    | 1.76 (1.45–2.12) | 0        | 0.69     | 0.00 (0.00–5.36) | 114      | 64.02    | 1.78 (1.47–2.14)  |
| Thyroid                             | 183      | 85.21    | 2.15 (1.85–2.48) | 1        | 0.12     | 8.06 (0.20–44.93) | 182      | 85.09    | 2.14 (1.84–2.47)  |
| Hematologic malignancies            | 152      | 94.77    | 1.60 (1.36–1.88) | 3        | 1.26     | 2.39 (0.49–6.97) | 149      | 93.52    | 1.59 (1.35–1.87)  |
| All Others                          | 117      | 45.26    | 2.58 (2.14–3.10) | 1        | 0.40     | 2.47 (0.06–13.76) | 116      | 44.86    | 2.59 (2.14–3.10)  |

SIR Standardized incidence ratio; CI confidence interval; N/A not applicable.

doi:10.1371/journal.pone.0148597.t003
risk of subsequent liver cancer in breast cancer patients (Table D in S1 File). In contrast, the rising risk of male gender observed in the multivariate analysis echoes the findings shown by SIR analysis, which may further suggest the inherited aggressive nature of male breast cancer.

There were several limitations associated with the present study. First, the possibility of synchronous cancer could not be completely excluded. However, most of the patients underwent complete imaging and laboratory surveys for breast cancer staging upon receiving a diagnosis. The patterns of the SIRs were similar for the general cohort and cohorts that excluded patients who were diagnosed with second primary cancers within the first year following their breast cancer diagnosis (Table 3 and Table A in S1 File), suggesting that the number of synchronous cancers was minimized. Second, due to a limitation of the NHIRD database, we were unable to access several important clinical factors, such as disease stage and specific molecular profiles, including expression of estrogen receptor, progesterone receptor, HER2 and other genetic alterations such as BRCA. In addition, factors such as obesity, smoking, alcohol use, and family history of malignancy were not included in the database. Finally, the relative short follow-up period and small number of male patients in present study may limit the scope of observation. As carcinogenesis can occur over an extended period of time, a longer follow-up period may be necessary to detect certain types of cancer. Further studies with larger patient cohort and longer observation are warranted.

In conclusion, the results from our nationwide population-based study demonstrate that breast cancer patients have an increased risk of developing non-breast primary malignant disease compared with the general population, and the excess risk of cancer was significantly higher for male breast cancer patients and/or patients who were diagnosed with breast cancer at a younger age. Furthermore, male gender, older age, previous chemotherapy treatment and comorbidity with liver cirrhosis were independent predictors of second primary malignancy in breast cancer patients. Based on the longer survival periods that are currently achieved for breast cancer patients, more intensive surveillance for a second primary cancer in all breast

| Table 4. Risk factors for secondary primary cancers development in patients with breast cancer. Multivariable analysis: p<0.1 enter. |
|---|---|---|---|
| Variables | Univariate analysis | Multivariate analysis | |
|  | HR (95% CI) | P Value | HR (95% CI) | P Value |
| Age increases per 10 years | 1.46(1.42–1.50) | <0.001 | 1.45(1.40–1.49) | <0.001 |
| Gender (male) | 4.54(3.60–5.72) | <0.001 | 3.01(2.38–3.80) | <0.001 |
| Comorbidities | | | |
| Diabetes mellitus | 1.60(1.46–1.75) | <0.001 | 1.06(0.96–1.17) | 0.265 |
| COPD | 1.46(1.33–1.61) | <0.001 | 1.05(0.95–1.16) | 0.379 |
| Chronic kidney disease | 1.48(1.31–1.68) | <0.001 | 1.11(0.97–1.27) | 0.116 |
| Liver cirrhosis | 3.76(3.09–4.59) | <0.001 | 2.84(2.32–3.47) | 0.000 |
| Autoimmune diseases | 1.39(1.22–1.59) | <0.001 | 1.12(0.98–1.28) | 0.101 |
| Dyslipidemia | 1.55(1.43–1.69) | <0.001 | 1.08(0.99–1.19) | 0.096 |
| Breast Cancer Treatment | | | |
| Hormone treatment | 0.98(0.90–1.06) | 0.556 | | |
| Chemotherapy | 0.94(0.87–1.01) | 0.086 | 1.26(1.16–1.36) | <0.001 |
| Trastuzumab | 1.09(0.86–1.39) | 0.463 | | |
| Radiotherapy | 1.01(0.94–1.09) | 0.812 | | |

Abbreviation: COPD = Chronic obstructive pulmonary disease; ESRD = End-stage renal disease

All factors with p< 0.1 in univariate analyses were included in the Cox multivariate analysis.

doi:10.1371/journal.pone.0148597.t004
cancer patients, especially those patients exhibiting high-risk features, is needed to allow for earlier detection and treatment of second primary malignancies.

Supporting Information

S1 File. Supplementary tables. Table A. Standardized incidence ratios for specific cancer types among patients with breast cancer (including subsequent malignancy occurred within one year). Table B. Risk factors for uterine cancer development in patients with breast cancer. Table C. Risk factors for lung cancers development in patients with breast cancer. Table D. Risk factors for liver cancers development in patients with breast cancer.

(DOCX)

Acknowledgments

This study is support partially by Taiwan Clinical Oncology Research Foundation and grants 103-2325-B-075-002, 104-2628-B-075-001-MY3 from the Ministry of Science and Technology (Formerly National Science Council), Taiwan; MOHW103-TD-B-111-02, MOHW104-TDU-B-211-124-001, and MOHW105-TDU-B-211-134003 from the Center of Excellence for Cancer Research at Taipei Veterans General, the Ministry of Health and Welfare, Executive Yuan, Taiwan; Taipei Veterans General Hospital-National Yang-Ming University Excellent Physician Scientists Cultivation Program, No. 103-V-B-025, V103C-141, V103B-022, V103E10-001, V104C-151, V105C-067 and 104DHA0100480 from Taipei Veterans General Hospital.

The study is based in part on data from the National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health and managed by National Health Research Institutes. The interpretation and conclusions contained herein do not represent those of Bureau of National Health Insurance, Department of Health or National Health Research Institutes.

Author Contributions

Conceived and designed the experiments: MHH CJL CYL. Performed the experiments: MHH CJL CJT CMY. Analyzed the data: MHH CJL YWH CMY SCC SHC. Contributed reagents/materials/analysis tools: TJC CHT CJL. Wrote the paper: MHH CJL CJT YWH SCC SHC YPH CCS CYL.

References

1. Parkin DM, Fernandez LM (2006) Use of statistics to assess the global burden of breast cancer. Breast J 12 Suppl 1: S70–80. PMID: 16430400
2. Coughlin SS, Ekewume DU (2009) Breast cancer as a global health concern. Cancer Epidemiol 33: 315–318. doi: 10.1016/j.canep.2009.10.003 PMID: 19896917
3. Weiss JR, Moysich KB, Swede H (2005) Epidemiology of male breast cancer. Cancer Epidemiol Bio-markers Prev 14: 20–26. PMID: 15669471
4. Giordano SH (2005) A review of the diagnosis and management of male breast cancer. Oncologist 10: 471–479. PMID: 16079314
5. Shen Y-C, Chang C-J, Hsu C, Cheng C-C, Chiu C-F, et al. (2005) Significant Difference in the Trends of Female Breast Cancer Incidence Between Taiwanese and Caucasian Americans: Implications from Age-Period-Cohort Analysis. Cancer Epidemiology Biomarkers & Prevention 14: 1986–1990.
6. Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, et al. (2013) Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer.
7. Mellemkjaer L, Christensen J, Frederiksen K, Pukkala E, Weiderpass E, Bray F, et al. (2011) Risk of primary non-breast cancer after female breast cancer by age at diagnosis. Cancer Epidemiol Biomarkers & Prevention 20: 1784–1792. doi: 10.1158/1055-9965.EPI-11-0009 PMID: 21653644
8. Lee K-D, Chen S-C, Chan CH, Lu C-H, Chen C-C, Lin JT, et al. (2008) Increased Risk for Second Primary Malignancies in Women with Breast Cancer Diagnosed at Young Age: A Population-Based Study in Taiwan. Cancer Epidemiology Biomarkers & Prevention 17: 2647–2655.

9. Curtis RE, Ron E, Hankey BF, Hoover RN (2006) New Malignancies Following Breast Cancer. In: Curtis RE, Freedman DM, Ron E, et al eds. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973–2000. NIH Pub No 05–5302 Bethesda, MD: National Cancer Institute: 181–250.

10. Obedian E, Fischer DB, Hafty BG (2000) Second malignancies after treatment of early-stage breast cancer: lumpectomy and radiation therapy versus mastectomy. J Clin Oncol 18: 2406–2412. PMID: 10856100

11. Schaapveld M, Visser O, Louwman MJ, de Vries EGE, Willemsen PHB, Otter R, et al. (2008) Risk of New Primary Nonbreast Cancers After Breast Cancer Treatment: A Dutch Population-Based Study. Journal of Clinical Oncology 26: 1239–1246. doi: 10.1200/JCO.2007.11.9081 PMID: 18323547

12. Wang YP, Liu CJ, Hu YW, Chen TJ, Lin YT, Fung CP. (2012) Risk of cancer among patients with herpes zoster infection: a population-based study. Cmaj 184: E804–809. doi: 10.1503/cmaj.120518 PMID: 22988158

13. Chen SC, Teng CJ, Hu YW, Yeh CM, Hung MH, Hu LY, et al. (2015) Secondary primary malignancy risk among patients with esophageal cancer in Taiwan: a nationwide population-based study. PLoS One 10: e0116384. doi:10.1371/journal.pone.0116384 PMID: 25835388

14. Weiss JR, Moysich KB, Swede H (2005) Epidemiology of Male Breast Cancer. Cancer Epidemiology Biomarkers & Prevention 14: 20–26.

15. Shaitelman SF, Grills IS, Kestin LL, Ye H, Nandalur S, Huang J, et al. (2011) Rates of second malignancies after definitive local treatment for ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys 81: 1244–1251. doi:10.1016/j.ijrobp.2010.07.2005 PMID: 21030159

16. Wernberg JA, Yap J, Murekeiyosi C, Mashtare T, Wilding GE, Kulkarni SA. (2009) Multiple primary tumors in men with breast cancer diagnoses: a SEER database review. J Surg Oncol 99: 16–19. doi: 10.1002/jso.21153 PMID: 18937232

17. El Saghir NS, Seoud M, Khalil MK, Charafeddine M, Salem ZK, Geara FB, et al. (2006) Effects of young age at presentation on survival in breast cancer. BMC Cancer 6: 194. PMID: 16857060

18. Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. (2009) Breast cancer in young women: poor survival despite intensive treatment. PLoS One 4: e7695. doi:10.1371/journal.pone.0007695 PMID: 19907646

19. Mellemkjaer L, Friis S, Olsen JH, Scelo G, Hemminki K, Tracey E, et al. (2006) Risk of second cancer among women with breast cancer. Int J Cancer 118: 2285–2292. PMID: 16342146

20. Kroger N, Damon L, Zander AR, Wandt H, Derigs F, Ferante P, et al. (2003) Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients. Bone Marrow Transplant 32: 1153–1157. PMID: 14647269

21. Malone KE, Begg CB, Haile RW, Borg A, Concannon P, Tellhed L, et al. (2010) Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol 28: 2404–2410. doi: 10.1200/JCO.2009.24.2495 PMID: 20368571

22. Tuttler S, Tantraver MD, Guven GS (2012) Cowden syndrome: a major indication for extensive cancer surveillance. Med Oncol 29: 1365–1368. doi:10.1007/s12032-011-9896-x PMID: 21394636

23. Nelson HD, Fu R, Goddard K, Mitchell JP, Okinaka-Hu L, Rongwei F. (2013) U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: Systematic Review to Update the US Preventive Services Task Force Recommendation. Rockville (MD): Agency for Healthcare Research and Quality (US).

24. Hashibe M, Brennan P, Benhamou S, Castellsague X, Chen C, Curado MP, et al. (2007) Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst 99: 777–789. PMID: 17505073

25. Mannino DM, Buist AS (2007) Global burden of COPD: risk factors, prevalence, and future trends. Lancet 370: 765–773. PMID: 17765526

26. Kalaitzakis E, Gunnarsdottir SA, Joseffson A, Bjornsson E (2011) Increased risk for malignant neoplasms among patients with cirrhosis. Clin Gastroenterol Hepatol 9: 168–174. doi: 10.1016/j.cgh.2010.10.014 PMID: 21029788